Tomoyuki Fujisawa
Direttore operativo presso Whiz Partners, Inc.
Provenienza dei contatti di primo grado di Tomoyuki Fujisawa
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Whiz Partners, Inc.
 Whiz Partners, Inc. Investment ManagersFinance Whiz Partners, Inc. (Whiz Partners) is an independent venture capital firm headquartered in Tokyo, Japan. It became a separate entity from its former brand, CSK Venture Capital Co., Ltd. The firm was founded by Toshio Ando, Atsushi Matsumura, and Junichi Kajimoto in 2010.
11
| Private Company | Investment Managers | 11 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Tomoyuki Fujisawa tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| AXEL MARK INC. | Advertising/Marketing Services | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| ALBERT | Packaged Software | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| NANO MRNA CO.,LTD. | Pharmaceuticals: Other | Director/Board Member Chairman Director/Board Member | |
| ADVANCED MEDIA, INC. | Packaged Software | Director/Board Member Director/Board Member | |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
Adaptate Biotherapeutics Ltd.
 Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| Iron City Micro Display, Inc. | Director/Board Member | ||
IgniteEye Corp.
 IgniteEye Corp. Packaged SoftwareTechnology Services IgniteEye Corp. engages in the provision of cloud services for recruitment activities. Its cloud products include SONAR, Compass, Sniping and CREATIVE. The company was founded by Takashi Yoshida in May 2013 and is headquartered in Tokyo, Japan. | Packaged Software | Director/Board Member | |
| BANK OF JAPAN | General Government | Corporate Officer/Principal | |
ARTham Therapeutics, Inc.
 ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Pharmaceuticals: Major | Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin | |
| Sidney Kimmel Medical College | College/University | Doctorate Degree | |
| 82VS | Investment Managers | President | |
Axcelead Drug Discovery Partners, Inc.
 Axcelead Drug Discovery Partners, Inc. Miscellaneous Commercial ServicesCommercial Services Axcelead Drug Discovery Partners, Inc. is a Japanese company founded in 2017 that provides services for the quality evaluation of new modality regenerative medical cells, effectiveness and safety evaluation of target cells, and bridging data. The company is based in Fujisawa, JP. and has subsidiaries in the United States. It is used by more than 100 facilities such as clients pharmaceutical companies, venture companies, and academia. Axcelead offers non-clinical development strategic planning and problem resolution services to its clients. | Miscellaneous Commercial Services | Director/Board Member | |
| SHATTUCK LABS, INC. | Biotechnology | Director/Board Member | |
Tokai Tokyo Securities Europe Ltd.
 Tokai Tokyo Securities Europe Ltd. Investment Banks/BrokersFinance Part of Tokai Tokyo Financial Holdings, Inc., Tokai Tokyo Securities Europe Ltd. is a British company that provides security and flotation services. The company is based in London, UK. The company was founded in 2007. The CEO is Yoshihiko Kasahara. | Investment Banks/Brokers | Director/Board Member | |
| OBIC CO.,LTD. | Information Technology Services | Director/Board Member | |
| Natori Law Office | Corporate Officer/Principal | ||
SBI Savings Bank Co., Ltd.
 SBI Savings Bank Co., Ltd. Major BanksFinance SBI Savings Bank Co., Ltd. is engaged in providing banking services. It supports credit association. The company was founded on October 20, 1971 and is headquartered in Seoul, South Korea. | Major Banks | Director/Board Member | |
Mitsubishi UFJ Securities Holdings Co., Ltd.
 Mitsubishi UFJ Securities Holdings Co., Ltd. Investment Banks/BrokersFinance Mitsubishi UFJ Securities Co. Ltd. provides securities services including dealing, brokering, underwriting, and distribution. It also provides management and investment, venture capital, real estate leasing, insurance agency, and data processing systems development. The company was founded on March 4, 1948 and is headquartered in Tokyo, Japan. | Investment Banks/Brokers | Comptroller/Controller/Auditor | |
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.
 Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. Investment Banks/BrokersFinance Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. (MUMSS) is an independent securities brokerage firm headquartered in Tokyo, Japan. The firm was founded in 1948 through a joint venture between Mitsubishi UFJ Securities Holdings Co. Ltd. and Morgan Stanley Japan Holdings Co. Ltd. MUMSS offers domestic retail brokerage services to corporate and institutional clients. | Investment Banks/Brokers | Comptroller/Controller/Auditor | |
| CRI MIDDLEWARE CO., LTD. | Packaged Software | Director/Board Member | |
Glamo, Inc.
 Glamo, Inc. Computer CommunicationsElectronic Technology Glamo, Inc. engages in IoT platform, system license, and hardware original equipment manufacturer (OEM) businesses. Its products include iRemocon and Glamo Smart Lock. The company was founded by Isao Goto on February 2, 2011 and is headquartered in Tokyo, Japan. | Computer Communications | Director/Board Member | |
| KIDSWELL BIO CORPORATION | Biotechnology | Director/Board Member | |
| CARNA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
| University of Tokyo | College/University | Undergraduate Degree | |
Axel Mark, Inc. (Venture Capital)
 Axel Mark, Inc. (Venture Capital) Investment ManagersFinance Axel Mark Inc (Axel Mark) is a venture capital firm arm of Axel Mark Inc founded in 2015. The firm is headquartered in Tokyo, Japan. | Investment Managers | President | |
| Froute Mobile Technology KK | President | ||
| Axel Gamestudio, Inc. | President | ||
ActualEyes, Inc.
 ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka. | Packaged Software | Director/Board Member |
Statistiche
Distribuzione geografica
| Giappone | 24 |
| Stati Uniti | 9 |
| Regno Unito | 3 |
| Corea del Sud | 2 |
Settori
| Technology Services | 9 |
| Finance | 8 |
| Health Technology | 7 |
| Commercial Services | 4 |
| Consumer Services | 4 |
Posizioni
| Director/Board Member | 45 |
| President | 7 |
| Private Equity Investor | 7 |
| Chairman | 4 |
| Founder | 3 |
Contatti più connessi
| Insiders | |
|---|---|
| Victor Stone | 12 |
| Satoru Iino | 11 |
| Takashi Ejiri | 8 |
| Junji Oshita | 7 |
| Atsushi Matsumura | 5 |
| Hiroshi Takeda | 3 |
| Yuki Hasegawa | 3 |
| Toshio Ando | 2 |
| Shinya Kada | 2 |
| Junichi Kajimoto | 1 |
| Tatsuro Kochi | 1 |
- Borsa valori
- Insiders
- Tomoyuki Fujisawa
- Connessioni Società
